NAT GENET: 卵巢癌的12个新易感性位点

2017-03-30 MedSci MedSci原创

上皮性卵巢癌(EOC)是一种异质性疾病,通常分为侵袭性疾病(高级浆液(HGSOC),低度浆液(LGSOC),粘液性(MOC),子宫内膜样(ENOC)和透明细胞(CCOC))五种主要组织型和边界性疾病的两种组织型(浆液性和粘液性)。

近日,来自美国佛罗里达州坦帕市癌症流行病学部,莫菲特癌症中心的研究人员报道了一项关于卵巢癌12个新易感性位点的研究,相关研究成果刊登于国际杂志Nature Genetics上。

上皮性卵巢癌(EOC)是一种异质性疾病,通常分为侵袭性疾病(高级浆液(HGSOC),低度浆液(LGSOC),粘液性(MOC),子宫内膜样(ENOC)和透明细胞(CCOC))五种主要组织型和边界性疾病的两种组织型(浆液性和粘液性)。

之前的研究指出,一些基因,如BRCA1BRCA2的继承性缺陷约占遗传成分的40%。这些缺陷在人群中并不常见,约300人中有一人,并且与卵巢癌和乳腺癌的风险相关,BRCA1约为50%,BRCA2平均为16%。研究人员之前已经确定了27种常见癌风险相关基因突变,不过其中仅有少量与卵巢癌罕见亚型相关,总体来说变异只占疾病遗传成分的约4%。在一项多达10万人(包括17,000名最常见类型的卵巢癌患者)的遗传分析研究中,研究人员确定了12种新的增加卵巢癌患病风险的遗传变异,并找到了它们与以前发表的18种变异之间的关联。

研究人员为了鉴定与不同组织型上皮性卵巢癌(EOC)相关的常见等位基因,汇集了来自多个全基因组基因分型项目的数据,共计25,509例平均年龄组和40,941例对照。之后他们又分析了另外31,000BRCA1BRCA2突变携带者,其中包括近4000名卵巢上皮癌患者。从这些分析中,研究人员识别出了患癌风险有关的另外12个突变,并确认这些突变与18个之前发布的突变之间的关联。

原始出处:

Catherine M Phelan, Karoline B Kuchenbaecker,Jonathan P Tyrer. et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics (2017) doi:10.1038/ng.3826

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881827, encodeId=e302188182e40, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 28 05:45:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733841, encodeId=9c3a1e33841c7, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Jul 25 21:45:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048803, encodeId=8c71204880368, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 23 13:45:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686075, encodeId=1c2516860e579, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Dec 01 13:45:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460522, encodeId=1ed61460522fb, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Fri Mar 31 23:45:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]
    2017-05-28 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881827, encodeId=e302188182e40, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 28 05:45:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733841, encodeId=9c3a1e33841c7, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Jul 25 21:45:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048803, encodeId=8c71204880368, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 23 13:45:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686075, encodeId=1c2516860e579, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Dec 01 13:45:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460522, encodeId=1ed61460522fb, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Fri Mar 31 23:45:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]
    2017-07-25 canlab
  3. [GetPortalCommentsPageByObjectIdResponse(id=1881827, encodeId=e302188182e40, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 28 05:45:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733841, encodeId=9c3a1e33841c7, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Jul 25 21:45:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048803, encodeId=8c71204880368, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 23 13:45:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686075, encodeId=1c2516860e579, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Dec 01 13:45:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460522, encodeId=1ed61460522fb, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Fri Mar 31 23:45:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]
    2017-11-23 cy0324
  4. [GetPortalCommentsPageByObjectIdResponse(id=1881827, encodeId=e302188182e40, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 28 05:45:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733841, encodeId=9c3a1e33841c7, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Jul 25 21:45:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048803, encodeId=8c71204880368, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 23 13:45:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686075, encodeId=1c2516860e579, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Dec 01 13:45:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460522, encodeId=1ed61460522fb, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Fri Mar 31 23:45:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1881827, encodeId=e302188182e40, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 28 05:45:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733841, encodeId=9c3a1e33841c7, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Jul 25 21:45:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048803, encodeId=8c71204880368, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 23 13:45:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686075, encodeId=1c2516860e579, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Dec 01 13:45:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460522, encodeId=1ed61460522fb, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Fri Mar 31 23:45:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]

相关资讯

Wien Med Wochenschr:上皮性卵巢癌新近进展

近日,维也纳医科大学综合癌症中心的Stefanie Aust等对上皮性卵巢癌(eoc)生物学研究的最新概况进行总结,并将其发表在Wien Med Wochenschr杂志上。研究人员重点关注了EOC的起源、复杂的异质性和最新治疗方法。另外,肿瘤微环境的作用、腹膜腔传播的高度可能性和新的分子生物学研究结果也在本文中进行了总结。 最新的分子生物学特性将上皮性卵巢癌(EOC)作为一种高度异